Kairos Pharma Secures Department of Defense Grant to Advance Lung Cancer Biomarker Research

Kairos Pharma Ltd. has received a Department of Defense grant to further its groundbreaking research in cancer therapeutics, specifically focusing on lung cancer biomarker development. The company's lead candidate, ENV105, represents a significant potential advancement in addressing drug resistance in cancer treatments.

The research targets CD105, a protein identified as a critical driver of treatment resistance across multiple cancer types. By developing an antibody that specifically targets this protein, Kairos aims to restore the effectiveness of standard cancer therapies and potentially improve patient outcomes.

Currently, the company is advancing two clinical trials for ENV105, one in prostate cancer and another in EGFR-dependent non-small cell lung cancer. Safety and interim efficacy results are anticipated in the second quarter of 2025, marking a critical milestone in the company's research trajectory.

The Department of Defense grant provides non-dilutive funding that supports Kairos Pharma's innovative approach to oncology. This external validation underscores the potential significance of the company's research in addressing significant unmet medical needs in cancer treatment.

In addition to ENV105, Kairos is developing KROS101, an immune response modulator, which has already garnered attention through presentations at key oncology conferences. The company's robust intellectual property portfolio, extending into the 2030s, positions it strategically in the competitive biotechnology landscape.

The research holds profound implications for cancer treatment. By targeting CD105, which contributes to treatment resistance, ENV105 could potentially transform how clinicians approach cancer therapies, particularly in lung and prostate cancers where current treatment options remain limited.

With support from financial analysts and a growing trial network, Kairos Pharma continues to advance its mission of developing innovative oncology therapeutics that can overcome drug resistance and improve patient survival rates.